Central Laboratory, Shenzhen Bao'an District Songgang People's Hospital, Shenzhen, China.
Department of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Front Immunol. 2024 Oct 4;15:1477196. doi: 10.3389/fimmu.2024.1477196. eCollection 2024.
Bladder cancer (BCa) is a common malignancy in the urinary tract. It has high recurrence rates and often requires microscopic examination, which presents significant challenges in clinical treatment. Previous research has shown that circular TAF4B (circTAF4B) is significantly upregulated in BCa and is associated with a poor prognosis. However, the specific targets and molecular mechanisms by which circTAF4B functions in BCa are still not well - understood.
In this study, an RNA pull - down assay and mass spectrometry were utilized to identify MFN2 as a binding protein of circTAF4B. Additionally, siRNA was used to silence MFN2 to observe the amplification of the inhibitory effects of circTAF4B overexpression on cell growth and migration in BCa cells. Moreover, circTAF4B shRNA lentiviral particles were employed to study their impact on BCa progression by examining the regulation of p27 and the blocking of AKT signaling.
It was found that MFN2 is a binding protein of circTAF4B. Silencing MFN2 with siRNA enhanced the inhibitory effects of circTAF4B overexpression on cell growth and migration in BCa cells. Also, circTAF4B shRNA lentiviral particles inhibited BCa progression by upregulating p27 and blocking AKT signaling.
In conclusion, the physical binding of circTAF4B to MFN2 is a crucial process in the tumorigenesis and progression of BCa. Targeting circTAF4B or its complexes may have potential as a therapeutic strategy for BCa diagnosis and treatment.
膀胱癌(BCa)是一种常见的泌尿道恶性肿瘤。它具有较高的复发率,通常需要进行显微镜检查,这在临床治疗中带来了巨大的挑战。先前的研究表明,环状 TAF4B(circTAF4B)在膀胱癌中显著上调,与不良预后相关。然而,circTAF4B 在膀胱癌中发挥作用的具体靶点和分子机制仍不清楚。
在这项研究中,我们利用 RNA 下拉实验和质谱技术鉴定 MFN2 是 circTAF4B 的结合蛋白。此外,我们使用 siRNA 沉默 MFN2,观察 circTAF4B 过表达对膀胱癌细胞生长和迁移的抑制作用的放大。此外,我们使用 circTAF4B shRNA 慢病毒颗粒研究它们对 BCa 进展的影响,通过检查 p27 的调节和 AKT 信号的阻断来评估。
研究发现,MFN2 是 circTAF4B 的结合蛋白。用 siRNA 沉默 MFN2 增强了 circTAF4B 过表达对膀胱癌细胞生长和迁移的抑制作用。此外,circTAF4B shRNA 慢病毒颗粒通过上调 p27 和阻断 AKT 信号抑制 BCa 进展。
总之,circTAF4B 与 MFN2 的物理结合是 BCa 发生和进展的关键过程。靶向 circTAF4B 或其复合物可能成为 BCa 诊断和治疗的潜在治疗策略。